Science 37

Science 37 Holdings, Inc. aims to revolutionize clinical research by providing universal trial access for patients, as reflected in its slogan, "Faster. More Inclusive. Patient-Friendly. Clinical Research that Works for Everyone." Founded in 2014 and based in the United States, the company's Metasite™ expands trial participation beyond traditional sites, fostering greater patient diversity. This unique approach allows patients to participate from home, local providers, or traditional sites, enhancing flexibility. The Metasite is supported by a proprietary technology platform and in-house medical and operational experts to ensure uniform study orchestration, compliance, and high-quality data. Notably, Science 37 recently secured a substantial $200.00M Post-IPO Equity investment on 07 October 2021, with backing from prominent investors including Lux Capital, Casdin Capital, Pura Vida Investments, BlackRock, Redmile Group, LifeSci Venture Partners, PPD Inc., RTW Investments, Samsara BioCapital, and Mubadala Capital Ventures. This infusion of capital reaffirms investor confidence in the company's innovative approach to advancing clinical research. For more information, visit www.science37.com or email [email protected].